BPC-157 Research Overview — Origin, Preclinical Data, and the Replication Problem

What BPC-157 is

BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide (15 amino acids, sequence GEPPPGKPADDAGLV) derived from a partial fragment of a larger gastric juice protein identified by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. It is produced by solid-phase peptide synthesis; no BPC-157 on the research market is isolated from biological sources.

It is not approved as a drug. It is not in any Health Canada, FDA, or EMA drug register. In Canada, BPC-157 is sold only as a research chemical for non-clinical laboratory use.

The Sikiric programme in Zagreb

The origin story is important because it explains the shape of the literature. Sikiric's group identified the parent protein in gastric juice in the 1990s, synthesised the active fragment, and published an extensive series of rodent studies over the following three decades covering:

• Gastrointestinal protection — NSAID-induced ulcers, inflammatory bowel models, esophagogastric lesions.
• Tendon and ligament healing — Achilles tenotomy, transection models, medial collateral ligament injury.
• Muscle crush injury — recovery of contractile function and histology after controlled trauma.
• Central nervous system models — encephalopathy, stroke, traumatic brain injury in rodents.
• Vascular effects — nitric oxide pathway modulation, bypass of thrombosed vessels.

Proposed mechanisms include activation of the nitric oxide system, upregulation of VEGF receptor 2 (VEGFR2), modulation of growth-hormone receptor expression, and effects on early growth response protein 1. Whether these are primary drivers or downstream markers is not resolved in the literature.

The replication picture

A small number of independent groups have reproduced individual findings. Chang and colleagues (J Appl Physiol 2011) reported that BPC-157 accelerated tendon healing in a rat Achilles model with documented histology and mechanical testing. Other independent publications exist on gastrointestinal and musculoskeletal endpoints. But the overall picture is that the majority of the published literature originates from the Zagreb group, and large-scale independent replication remains limited.

This is not the same as saying the findings are wrong. It is saying that the evidence base is concentrated in one research programme — which, for any researcher reading the literature, is a relevant methodological caveat to weigh alongside the reported effect sizes.

Human data

There are, as of 2026, no completed, peer-reviewed, adequately powered, placebo-controlled human clinical trials of BPC-157 for any indication. There are case reports, pilot investigations, and safety observations scattered across the literature, but nothing that would meet the evidentiary bar for regulatory approval. The absence of human data is why BPC-157 is not in any drug approval process — not because it is prohibited, but because the trials have not been done.

Mechanism, briefly

The most-cited proposed mechanisms in the preclinical literature:

1. Nitric oxide system modulation. BPC-157 appears to interact with the NO system in ways that produce both vasodilatory and cytoprotective effects in gastric and vascular tissue models.
2. VEGFR2 activation. Several papers report that BPC-157 promotes angiogenesis via VEGFR2, which could plausibly contribute to tissue repair in wound and tendon models.
3. Growth-factor upregulation. Reports of increased growth-hormone receptor expression and altered expression of repair-associated genes in injured tissue.

None of these mechanisms have been confirmed in human tissue under controlled clinical conditions.

The Canadian research framing

Because BPC-157 has no drug approval, it exists in Canada only as a research chemical. A Canadian researcher working with BPC-157 should:

• Source from a domestic vendor with a per-batch HPLC COA (≥98% purity) and mass-spectrometry identity confirmation.
• Store lyophilised material at -20°C; reconstituted material refrigerated and used within 2–4 weeks.
• Keep a full audit trail — invoice, batch number, COA, reconstitution log — consistent with institutional research norms.

See the BPC-157 encyclopedia entry for the full chemistry, structural details, and current Canadian stock status. For related tissue-repair research peptides, see TB-500 (the synthetic fragment of thymosin beta-4).

Summary

BPC-157 has a sizeable preclinical literature on tendon, ligament, and gastrointestinal healing, a plausible if unresolved mechanistic story, and essentially no human clinical evidence. It is not a drug, not approved anywhere, and is sold in Canada strictly as a research chemical. For a researcher, the literature is worth reading — with the concentration and replication caveats kept firmly in view.